Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Las Vegas Sands Corp. (LVS) vs Medtronic PLC (MDT) Price & Performance

Las Vegas Sands Corp.Trade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Las Vegas Sands Corp. vs Medtronic PLC — how do they compare? Las Vegas Sands Corp. trades at $45.95 (market cap $30.36B), while Medtronic PLC trades at $83.21 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 3.5× Las Vegas Sands Corp.'s market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.

LVSMDT
Market Cap
$30.36B$106.61B
Sector
Consumer CyclicalHealth
52-Week High
$69.49$105.35
52-Week Low
$44.78$73.75
Enterprise Value
$42.75B$125.36B
Dividend Yield
2.4%3.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Las Vegas Sands Corp.

LVS trades at $45.66, up 0.66% on the day, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.91 beating expectations. Revenue growth is robust, reaching $13.02B in 2025, and profitability metrics like a 49.59% gross margin and 94.53% ROE are impressive. The company maintains positive cash flow and recently paid a $0.30 dividend. Analyst sentiment is bullish with a $65.18 consensus price target, though technical indicators suggest near-term pressure.

The outlook for LVS is positive based on fundamental strength and analyst optimism, but risks include high debt levels and bearish technical trends. Investment opportunity lies in its earnings momentum and valuation upside, while investors should monitor debt management and market volatility. The stock's current price near support levels may present a entry point if fundamentals hold.

Medtronic PLC

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Las Vegas Sands Corp.

Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.

Read more on LVS

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT